Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sig-HELP-E7SH-kdel
- Development stage
- Unknown
- Lead developer
- Netherlands Cancer Institute
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
sig-HELP-E7SH-kdel is an investigational therapeutic DNA vaccine targeting the HPV16 E7 oncoprotein, developed by the Netherlands Cancer Institute (NKI-AVL). The vaccine is a plasmid-based construct (pUMVC3 backbone) encoding a shuffled (rearranged) HPV16 E7 sequence (E7SH) to prevent oncogenic transformation while maintaining immunogenicity. The construct is engineered with a signal peptide ('sig') for endoplasmic reticulum (ER) import, a KDEL retention signal to improve antigen processing and presentation by dendritic cells, and CD4 T-helper epitopes (HELP) to enhance the T-cell response. Administered via DNA tattoo vaccination, it has been evaluated in Phase I/II clinical trials for the treatment of HPV16-positive usual vulvar intraepithelial neoplasia (uVIN).
- Other names
- sig-HELP-E7SH-KDELsig-HELP-E-7SH-KDELsig-HELP-E 7SH-KDELHPV16 E7 DNA vaccineHPV-16 E7 DNA vaccineHPV 16 E7 DNA vaccine
02
Targets
MHC II (Major histocompatibility complex class II receptor)HLA-B7T-cell receptor specific for HPV16 E7 peptide–MHC complexesKDELR (KDEL endoplasmic reticulum lumen protein retaining receptor)HPV16 E7 (Human papillomavirus 16 E7 protein)
Beyond the preview
Go deeper on sig-HELP-E7SH-kdel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sig-HELP-E7SH-kdel.